New drug combo aims to control advanced breast cancer

NCT ID NCT06726148

First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 25 times

Summary

This study tests an experimental drug called ECI830, alone or with other cancer drugs (ribociclib and fulvestrant), in people with advanced hormone receptor-positive, HER2-negative breast cancer or certain solid tumors. The goal is to find safe doses and see if the combination can shrink tumors or slow disease progression. About 280 adults whose cancer has worsened after prior treatments will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HR+/HER2- BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Florida Cancer Specialists

    RECRUITING

    Fort Myers, Florida, 33901, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fred Hutch Cancer Research

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • MD Anderson Cancer Center Uni of Te

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Memorial Sloan Kettering

    RECRUITING

    New York, New York, 10017, United States

    Contact Email: •••••@•••••

    Contact

  • Novartis Investigative Site

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • Novartis Investigative Site

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Novartis Investigative Site

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Novartis Investigative Site

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Novartis Investigative Site

    RECRUITING

    Nanjing, Jiangsu, 210029, China

  • Novartis Investigative Site

    RECRUITING

    Xian, Shanxi, 710061, China

  • Novartis Investigative Site

    RECRUITING

    Brno, 656 53, Czechia

  • Novartis Investigative Site

    RECRUITING

    Copenhagen, DK-2100, Denmark

  • Novartis Investigative Site

    RECRUITING

    Odense C, 5000, Denmark

  • Novartis Investigative Site

    RECRUITING

    Bordeaux, 33076, France

  • Novartis Investigative Site

    RECRUITING

    Saint-Herblain, 44805, France

  • Novartis Investigative Site

    RECRUITING

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Novartis Investigative Site

    RECRUITING

    Heidelberg, 69120, Germany

  • Novartis Investigative Site

    RECRUITING

    Ulm, 89081, Germany

  • Novartis Investigative Site

    RECRUITING

    Haifa, 3109601, Israel

  • Novartis Investigative Site

    RECRUITING

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    RECRUITING

    Modena, MO, 41124, Italy

  • Novartis Investigative Site

    RECRUITING

    Milan, 20141, Italy

  • Novartis Investigative Site

    RECRUITING

    Chuo Ku, Tokyo, 1040045, Japan

  • Novartis Investigative Site

    RECRUITING

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    RECRUITING

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    RECRUITING

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    RECRUITING

    Tainan, 704, Taiwan

  • Novartis Investigative Site

    RECRUITING

    London, Oxford, OX3 7LE, United Kingdom

  • SCRI Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact

    Contact Email: •••••@•••••

  • University of California LA

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • WA Uni School Of Med

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.